

Priority actions for the non-communicable disease crisis



Robert Beaglehole, Ruth Bonita, Richard Horton, Cary Adams, George Alleyne, Perviz Asaria, Vanessa Baugh, Henk Bekedam, Nils Billo, Sally Casswell, Michele Cecchini, Ruth Colagiuri, Stephen Colagiuri, Tea Collins, Shah Ebrahim, Michael Engelgau, Gauden Galea, Thomas Gaziano, Robert Geneau, Andy Haines, James Hospedales, Prabhat Jha, Ann Keeling, Stephen Leeder, Paul Lincoln, Martin McKee, Judith Mackay, Roger Magnusson, Rob Moodie, Modi Mwatsama, Sania Nishtar, Bo Norrving, David Patterson, Peter Piot, Johanna Ralston, Manju Rani, K Srinath Reddy, Franco Sassi, Nick Sheron, David Stuckler, Il Suh, Julie Torode, Cherian Varghese, Judith Watt, for The Lancet NCD Action Group and the NCD Alliance

The UN High-Level Meeting on Non-Communicable Diseases (NCDs) in September, 2011, is an unprecedented opportunity to create a sustained global movement against premature death and preventable morbidity and disability from NCDs, mainly heart disease, stroke, cancer, diabetes, and chronic respiratory disease. The increasing global crisis in NCDs is a barrier to development goals including poverty reduction, health equity, economic stability, and human security. *The Lancet* NCD Action Group and the NCD Alliance propose five overarching priority actions for the response to the crisis—leadership, prevention, treatment, international cooperation, and monitoring and accountability—and the delivery of five priority interventions—tobacco control, salt reduction, improved diets and physical activity, reduction in hazardous alcohol intake, and essential drugs and technologies. The priority interventions were chosen for their health effects, cost-effectiveness, low costs of implementation, and political and financial feasibility. The most urgent and immediate priority is tobacco control. We propose as a goal for 2040, a world essentially free from tobacco where less than 5% of people use tobacco. Implementation of the priority interventions, at an estimated global commitment of about US\$9 billion per year, will bring enormous benefits to social and economic development and to the health sector. If widely adopted, these interventions will achieve the global goal of reducing NCD death rates by 2% per year, averting tens of millions of premature deaths in this decade.

Introduction

The spread of non-communicable diseases (NCDs) presents a global crisis; in almost all countries and in all income groups, men, women, and children are at risk of these diseases.¹ Worldwide, substantial gains have been achieved in economic growth, health, and living standards in the past century. This progress is now threatened by crises of our own creation—climate change, finance and food insecurities,² and the crisis in NCDs, principally heart disease, stroke, diabetes, cancers, and chronic respiratory disease.³

The UN High-Level Meeting (UN HLM) on NCDs in September, 2011,⁴ provides an unrivalled opportunity to create a sustained rights-based global movement to tackle NCDs,⁵ analogous to the UN General Assembly Special Session on HIV infection and AIDS a decade ago, which concluded that dealing with the disease was central to the development agenda.⁶ Political leadership at the highest level, with international coordination and consensus for priority actions and interventions are crucial responses to the crisis in NCDs and to facilitate national action.⁷ A successful meeting will generate high-level and sustained political commitments to the priority actions needed globally and nationally to prevent and treat NCDs. It will ensure that NCDs become central to the long-term global development agenda.

In the interests of promoting a unified political message and a common voice, *The Lancet* NCD Action Group—an informal collaboration of academics, practitioners, and civil society organisations—and the NCD Alliance—comprising four key international non-governmental organisations (Union for International Cancer Control, International Union Against Tuberculosis and Lung

Disease, International Diabetes Federation, and World Heart Federation)—propose a shortlist of priority actions for NCDs: political leadership at the highest level, globally and nationally; immediate implementation of the priority interventions; building international coordination and consensus for priority actions and interventions; and establishment of monitoring, reporting, and accountability mechanisms for assessment of progress.

In this report, we synthesise and expand the evidence reported in four series in *The Lancet* in the past 5 years (panel 1) and focus on what matters most for NCDs.^{18–21} These reports, initiated by WHO and produced in collaboration with almost 100 leading scientists, support WHO's action plan for the prevention and control of NCDs.²² Here we address the topics of three round-table discussions proposed in the UN Modalities Resolution at the UN HLM: the NCD crisis; priority actions; and international cooperation. We conclude with a set of recommendations for the outcomes document from the UN HLM.

The NCD crisis NCD burden

The global burden of NCDs is increasing (panel 2), and is a major barrier to development and achievement of the Millennium Development Goals (MDGs). The underlying causes of these diseases are shared and modifiable risk factors; they are also major causes of health inequalities.²⁵

Shared risk factors and their causes

The main risk factors for NCDs for individuals are well known and are similar in all countries.²⁶ Tobacco use, foods high in saturated and trans fats, salt, and sugar

Published Online

April 6, 2011

DOI:10.1016/S0140-6736(11)60393-0

University of Auckland, Auckland, New Zealand (Prof R Beaglehole DSc, Prof R Bonita PhD); *The Lancet*, London, UK (R Horton FMedSci); NCD Alliance/Union for International Cancer Control, Geneva, Switzerland (C Adams MBA, J Torode PhD); Pan American Health Organization, Washington, DC, USA (G Alleyne MD, J Hospedales FFPH); School of Public Health, Imperial College, London, UK (P Asaria MPH); Commonwealth Secretariat, London, UK (V Baugh MSc); WHO/Western Pacific Regional Office, Manila, Philippines (H Bekedam MD, M Rani PhD, C Varghese MD); NCD Alliance/International Union Against Tuberculosis and Lung Disease (The Union), Paris, France (N Billo MD); Massey University, Auckland, New Zealand (Prof S Casswell PhD); Health Division, Organisation for Economic Co-operation and Development, Paris, France (M Cecchini MD, F Sassi PhD); NCD Alliance, Geneva, Switzerland (T Collins DrPH); South Asia Network for Chronic Disease, New Delhi, India (Prof S Ebrahim DM); World Bank, Washington, DC, USA (M Engelgau MD); WHO European Regional Office, Copenhagen, Denmark (G Galea MD); Brigham and Women's Hospital, Harvard Medical School, Boston, USA (T Gaziano MD); University of Ottawa, Ottawa, ON, Canada (R Geneau PhD); London School of Hygiene and Tropical Medicine, London, UK (Prof A Haines FMedSci, Prof M McKee MD, Prof P Piot MD); Centre for Global Health Research, Toronto, ON, Canada (Prof P Jha DPhil); NCD Alliance/International

Panel 1: Summary of evidence reported in *The Lancet Series*

2005

A proposed global goal of a reduction in non-communicable disease (NCD) death rates of 2% per year was estimated to avert 36 million deaths from these diseases over 10 years, more than half from cardiovascular disease.⁸

2007

Many possible interventions were assessed, and three priority cost-effective interventions were identified—tobacco control, salt reduction, and treatment of people at high risk of cardiovascular disease.^{9,10} Scale-up of these three interventions in 23 high-burden low-income and middle-income countries would easily achieve the global goal in these countries, and the yearly cost of implementation of the interventions was estimated to be about US\$6 billion (2005 US\$).¹¹

2009

Attention was drawn to several cost-effective interventions for harmful consumption of alcohol, and the need for concerted global and national responses.^{12–14}

2010

NCDs were judged to be a development issue,¹⁵ the interventions to prevent obesity were evaluated,¹⁶ and progress in the 23 high-burden countries was assessed.¹⁷

Panel 2: Increasing burden of non-communicable diseases (NCDs)

- Two of three deaths each year are attributable to NCDs. Four-fifths of these deaths are in low-income and middle-income countries, and a third are in people younger than 60 years.²³
- Overall, age-specific NCD death rates are nearly two-times higher in low-income and middle-income countries than in high-income countries.²⁴
- NCDs often cause slow and painful deaths after prolonged periods of disability.
- In all regions of the world, total numbers of NCD deaths are rising because of population ageing and the globalisation of risks, particularly tobacco use.
- In addition to the longstanding challenges of curtailing infectious disease, this double burden of disease places enormous strains on resource-deficient health systems.

Diabetes Federation, Brussels, Belgium (R Colagiuri BEEd, Prof S Colagiuri MBBS, A Keeling MA); University of Sydney, NSW, Australia (Prof S Leeder MD, Prof R Magnusson PhD); National Heart Forum, London, UK (P Lincoln BSc, M Mwatsama MSc); World Lung Foundation, Hong Kong, China (J Mackay FRCP); University of Melbourne, Melbourne, VIC, Australia (Prof R Moodie MBBS); HeartFile, Islamabad, Pakistan (S Nishtar MD); World Stroke Organization, Geneva, Switzerland (Prof B Norrving MD); International Development Law Organization, Rome, Italy (D Patterson LL.M.); NCD Alliance/World Heart Federation, Geneva, Switzerland (J Ralston MS); Public Health Foundation of

(especially in sweetened drinks), physical inactivity, and the harmful consumption of alcohol cause more than two-thirds of all new cases of NCDs and increase the risk of complications in people with NCDs. Tobacco use alone accounts for one in six of all deaths resulting from NCDs. Every day more than 1 billion people smoke or chew tobacco because of their addiction to nicotine, and about 15 000 die from tobacco-related diseases; tobacco use accounts for half the health inequalities, as assessed by education, in male mortality.²⁷ Tobacco use has fallen in many high-income countries, at least in men, but is now rising rapidly in many low-income and middle-income countries with a prevalence of more than 25% in adolescents in some countries. This rise is due to the tobacco industry's uncontrolled activities and persistent efforts to influence and weaken tobacco control policies.^{28,29}

Consumption of foods high in saturated and industrially produced trans fats, salt, and sugar is the cause of at least 14 million deaths or 40% of all deaths every year from NCDs.³⁰ For example, overconsumption

of salt causes up to 30% of all cases of hypertension.³¹ Physical inactivity causes about 3 million or 8% of all deaths per year from NCDs. Alcohol consumption leads to 2·3 million deaths each year, 60% of which are due to NCDs, and has adverse health, social, and economic effects, and not just for the people who drink.^{32,33}

Changes in the social and economic environment have resulted in the risk factors for NCDs becoming widespread.¹⁵ Figure 1 shows that the choices for tobacco and alcohol use, diets, and physical activity are influenced by forces that are outside the control of individuals, especially children. Agricultural subsidies, and trade and capital market liberalisation have contributed to reduced prices and increased availability of unhealthy products, and to the increasing rates of risks now noted among young people, leading to a rapid rise in the proportion who are overweight.³⁴

NCDs: a barrier to development

The burden of NCDs is increasing in low-income and middle-income countries, contributing to poverty and becoming a major barrier to development and achievement of the MDGs (figure 1). NCDs disproportionately affects individuals who are poor thus increasing inequalities.²⁵ People who are poor live in settings where policies, legislation, and regulations to tackle NCDs either do not exist or are inadequate. Additionally, reduced access to comprehensive services for prevention and treatment of NCDs arise because of financial reasons and weak health systems.

NCDs also cause poverty. Most are chronic and can lead to continued expenditures that trap poor households in cycles of debt and illness, perpetuating health and economic inequalities. In India, one in four families in which a family member has cardiovascular disease has catastrophic expenditure; as a result, 10% of these families are driven into poverty.³⁵ NCDs diminish household earnings and a family's ability to provide for and educate children; and expenditure on tobacco contributes to household poverty.³⁶

Household costs of NCDs have a substantial macroeconomic effect. The loss of productivity reduces a society's effective labour force, resulting in reductions in overall economic output. For every 10% rise in mortality from NCDs, the yearly economic growth is estimated to be reduced by 0·5%.³⁷ On the basis of this evidence, the World Economic Forum now ranks NCDs as one of the top global threats to economic development.³⁸ If development efforts are to be successful, they must include all diseases that trap households in cycles of illness and poverty, irrespective of their cause. For example, progress towards reducing rates of tuberculosis is impeded by coexisting epidemics of HIV and NCD.³⁹ Tobacco is an important risk factor for the spread of tuberculosis, largely because it is so widely available—eg, it accounts for up to half of all deaths from tuberculosis in India.⁴⁰ The importance of prenatal and early life

exposures to the later development of obesity suggests that efforts to prevent obesity, should be included in maternal and child health, and nutrition programmes.⁴¹

Priority interventions for NCDs

Selection criteria

The priority interventions chosen for immediate attention need to meet rigorous, evidence-based criteria: a substantial effect on health (reduction in premature deaths and disability); strong evidence for cost-effectiveness; low costs of implementation; and political and financial feasibility for scale-up. There are many possible interventions for NCDs.^{42,43} However, the most robust available evidence for the effectiveness and effect of interventions is to lower the prevalence of the major risk factors through population-wide methods directed at everyone, and to target treatment to people at high risk of NCDs, particularly cardiovascular disease. Not all interventions are cost effective or affordable in terms of resources and equity; the feasibility of implementation and scale-up of interventions in all countries must also be considered. Panel 3 shows the criteria according to which interventions should be chosen.

We propose five immediate priority interventions—four population-wide and one for clinical services (delivery of essential drugs and technologies)—which are highly cost effective in low-resourced countries, and will avert premature deaths and disability from NCDs in the population. The feasibility for scale-up depends on many factors: the political situation; resource availability; health-system capacity; community support; the power of commercial interests; experiences of other countries; and international commitments and support. Our assessment of feasibility is subjective since no overall method of measurement is recognised.

These five recommended cost-effective interventions have been addressed in *The Lancet Series* (table)^{9,10,13,16} and are affordable in almost all countries. Drugs for diabetes and cancer have not yet been formally assessed in the same way as has the multidrug combination for cardiovascular disease. The recommendation for palliative care is based solely on human-rights considerations.

Interventions with a high impact on health and high feasibility, such as tobacco control and salt reduction, are directed towards whole populations and will have the greatest benefits, be pro-poor, and reduce inequalities. These interventions should be given priority for full implementation in all countries. Population-wide interventions have advantages over targeted strategies—most people will be exposed to their positive effects; the costs of implementation are very low; extensive health-systems strengthening is not needed; and those already suffering from or at high risk of NCDs will also benefit.

Accelerated tobacco control

The priority for immediate action is to achieve a suggested global goal by 2040 of a world essentially free




Figure 1: Associations between poverty, non-communicable diseases (NCDs), and development goals⁴⁵ MDG=Millennium Development Goal.

Panel 3: Criteria for immediate priority interventions

- Cost-effectiveness reported for many countries, and estimated either to save costs or to cost less than about US\$1000 per disability-adjusted life-year averted
- Implementation costs are known and affordable in most countries, and evidence for the effect on population health has been assessed and the intervention is likely to make a large contribution to the achievement of the global goal—ie, a reduction in death rates of 2% per year
- A range of projects or case studies has demonstrated successful implementation
- Interventions are feasible to scale up—economically, politically, and programmatically—in most countries

Interventions	Cost per person per year (US\$)			
	China	India	Russia	
1. Tobacco use	Accelerated implementation of the WHO Framework Convention on Tobacco Control ⁹	0.14	0.16	0.49
2. Dietary salt	Mass-media campaigns and voluntary action by food industry to reduce consumption ⁹	0.05	0.06	0.16
3. Obesity, unhealthy diet, and physical inactivity	Mass-media campaigns, food taxes, subsidies, labelling, and marketing restrictions ¹⁶	0.43	0.35	1.18
4. Harmful alcohol intake	Tax increases, advertising bans, and restricted access ¹³	0.07	0.05	0.52
5. Cardiovascular risk reduction	Combination of drugs for individuals at high risk of NCDs ¹⁰	1.02	0.90	1.73
Total cost per person*	..	1.72	1.52	4.08

*Excludes any cost synergies or future treatment cost savings.

Table: Estimated costs of five priority interventions for non-communicable diseases (NCDs) in three countries¹⁶

Panel 4: WHO Framework Convention on Tobacco Control (FCTC)

The FCTC, the first international health treaty adopted by the World Health Assembly in 2003, has been ratified by more than 170 countries. FCTC emphasises methods that are both effective and cost effective:⁴⁴

- Reduce demand for tobacco products by methods such as raising tobacco taxes, legislation of health warnings, smoke-free work and public places, and a complete ban on all forms of tobacco promotion; and
- Supply-side intervention, especially to control the illicit trade in tobacco products

The FCTC is a new approach to international health cooperation, which is crucial to the success of the FCTC along with leadership, commitment, and political will among all stakeholders. In 2009, only 10% of the world's population was covered by key FCTC methods.⁴⁵

A top priority of the UN High-Level Meeting on Non-Communicable Diseases is to strengthen political resolve for the accelerated implementation of all aspects of the FCTC and other methods needed to achieve a world essentially free of tobacco (prevalence <5%).

India, New Delhi, India (Prof K Srinath Reddy DM); University of Southampton, Southampton, UK (N Sheron FRCP); Harvard University, Boston, MA, USA (D Stuckler PhD); Yonsei University College of Medicine, Seoul, South Korea (Prof I Suh PhD); and London, UK (J Watt BA)

Correspondence to:

Prof Robert Beaglehole, 42 Albert Road, Devonport, Auckland 0624, New Zealand r.beaglehole@auckland.ac.nz

For more on WHO Framework Convention on Tobacco Control see <http://www.who.int/fctc/en>

from tobacco where less than 5% of the population use tobacco. Full implementation of four of the Framework on Tobacco Control (FCTC) strategies would avert 5·5 million deaths over 10 years in 23 low-income and middle-income countries with a high burden of NCD.⁹ An important outcome from the UN HLM will be renewed resolve to accelerate the full implementation of all aspects of the FCTC (panel 4). This action will have immediate health and economic benefits because reduction in exposure to tobacco smoke, both direct and second hand, will reduce the burden of cardiovascular disease within 1 year and thus health expenditures.^{46,47}

Salt reduction

Reduction in salt consumption is the other top priority because it will lead to lower blood pressure, one of the main risk factors for stroke and heart disease. Reduction of population-wide salt consumption by only 15%—through mass-media campaigns and reformulation of food products by industry—would avert up to 8·5 million deaths in 23 high-burden countries over 10 years.⁹ In the long term, the reduction in salt consumption will have a greater effect since reduced intake will attenuate the age-associated blood pressure rise, and any small risk of iodine deficiency can be addressed by other means.⁴⁸ Salt substitution in countries such as China, where much of the salt is added during cooking and eating, will be a useful strategy.⁴⁹ As the consumption of processed foods rises in many countries, a change in the industry norms to reduce the addition of salt now will have important benefits in the future,⁵⁰ although government regulation might be needed. Our suggested global goal is to reduce worldwide salt intake to less than 5 g (or 2000 mg sodium) per person per day⁵¹ by 2025.

Promotion of healthy diets and physical activity

Policies to promote physical activity and the consumption of foods low in saturated and trans fats, salt, and sugar—

particularly sugar-sweetened drinks—will lead to wide-ranging health gains, including prevention of overweight (especially in children), cardiovascular disease, and some cancers,⁵² and improved oral and periodontal health. These policies might largely pay for themselves through their reduction of health-care costs in the future, especially in low-income and middle-income countries.¹⁶ The main interventions include fiscal methods that increase the price of foods high in saturated and industrially produced trans fats and sugar; food labelling; and marketing restrictions of unhealthy food products, especially to children and young people.⁵³ The food industry in all countries should start to reformulate processed foods and stop the promotion of unhealthy products to children. Strong government encouragement, including regulatory and fiscal measures, will be needed to ensure rapid progress. Obesity prevention should be included in maternal and child health and nutrition programmes.⁴¹ Modification of the built environment to promote physical activity also has the potential to prevent obesity, and although it would be more challenging initially,⁵⁴ could rapidly advance as a co-benefit of climate control methods.⁵⁵

Reduction of harmful alcohol consumption

Policies that affect the price, promotion, and availability of alcohol reduce alcohol-related harms.¹³ Enforced legislation that reduces drink-driving, and interventions for at-risk drinkers are also effective. In countries with high amounts of unrecorded production and consumption, an important goal is to increase the proportion of alcohol that is taxed; it requires effective policing of illegal and informally produced alcohol. The imposition of a tax based on alcohol content is an essential complement to increased taxes. In most countries, and globally, alcohol marketing and sponsorship are widespread and, as with tobacco, legislative responses are needed to reduce harmful consumption of alcohol.

Access to essential drugs and technologies

Universal access to affordable and good-quality drugs for NCDs is an important issue for all countries, and especially low-income and middle-income countries. This issue also arises in the treatment of HIV infection and AIDS; an integrated approach is needed for the treatment of all priority diseases with special attention to reducing inequalities.

The best evidence-based clinical approach for NCDs in low-income and middle-income countries is a multidrug combination for people identified opportunistically in primary care as being at high risk of cardiovascular disease, or for patients who have already had a clinical event.¹⁰ WHO has produced risk assessment charts⁵⁶ that can be further simplified by removal of the need for a blood sample.⁵⁷ Scale-up of this intervention would, over 10 years, avert 18 million deaths from cardiovascular disease in 23 high-burden

low-income and middle-income countries at a cost of about US\$1.08 per person per year.¹⁰

Other drugs that have not yet been formally assessed for their effect on population health are also recommended. Insulin is essential for survival and treatment of people with type 1 diabetes; children and young people in many parts of the world die because they have no access to insulin.⁵⁸ Improved control of blood glucose, by behaviour change or low-cost drugs, reduces the development and progression of disabling complications in people with type 2 diabetes.⁵⁹

Many cancers are treatable with effective off-patent drugs that can be manufactured generically at affordable prices; that cancers remain untreated in many low-income and middle-income countries is unacceptable.⁶⁰ Liver cancer can be largely prevented with the hepatitis B vaccine. The cost has fallen substantially, and the vaccine is cost effective in high-risk populations and in countries where the infection is widespread. The prevention of cervical cancer is now possible with human papillomavirus vaccines, although the high cost and the challenge of delivery to adolescents are drawbacks.⁶¹ Palliation to relieve pain and reduce suffering should be available for people with cancers that are not treatable, yet it is still largely absent in many parts of the world.⁶²

The prevalence of asthma is increasing worldwide. Inhaled drugs for asthma control offer hope, although the cost-effectiveness of these drugs is an issue. An Asthma Drug Facility has been established to provide access to affordably priced, quality-assured asthma inhalers in resource-constrained settings.

Priority actions for the NCD

Key to progress

Although policies, strategies, plans, and calls to action are common in international and national reports,^{16,63,64} implementation has been slow. The reason for the delay is partly the pressing nature of other global health issues, and the long time for the messages about the global burden and preventability of NCDs to be developed and effectively disseminated. To achieve visibility on the global health agenda is difficult, but recognised ways for making progress do exist.^{15,65,66}

A prerequisite for delivery of the five immediate priority interventions is a set of priority actions (figure 2; panel 5). These include, both nationally and internationally: sustained political leadership at the highest levels; support for strengthening of health systems, particularly in primary health care; international cooperation; and monitoring systems and accountability mechanisms for measurement and reporting of progress.

Leadership

The first key action for success is strong and sustained political leadership at the highest national and international levels. This commitment will be the most




Figure 2: Five priority actions by countries and international agencies for the non-communicable disease (NCD) crisis

Panel 5: Five recommendations for action by countries and international agencies for the UN High-Level Meeting on Non-Communicable Diseases (NCDs)

Leadership

The most important outcome of the UN High-Level Meeting on NCDs will be sustained and strong high-level political support for a framework of specific commitments to tackle the NCD crisis with the aim of reducing NCD death rates by 2% per year.

Prevention

- Accelerate implementation of the WHO Framework Convention on Tobacco Control to achieve a world essentially free from tobacco by 2040, where less than 5% of people use tobacco
- Reduce salt intake to less than 5 g (2000 mg sodium) per person per day by 2025
- Align national policies on agriculture, trade, industry, and transport to promote improved diets, increase physical activity, and reduce harmful alcohol use

Treatment

- Deliver cost-effective and affordable essential drugs and technologies for all priority disorders
- Strengthen health systems to provide patient-centred care across different levels of the health system, starting with primary care

International cooperation

- Raise the priority of NCDs on global agendas, and increase funding for these diseases
- Promote synergies between programmes for NCDs and other global health priorities, including sustainability and mitigation of climate change

Monitoring, reporting, and accountability

- Identify ambitious targets and a transparent reporting system
- Assess progress on the priority actions and interventions
- Report regularly to the UN and other forums on progress on these national and international commitments

important outcome of the UN HLM. Individual champions and politicians will also need to take a leadership role. The health sector has a leading role in responding to NCDs, but many other government sectors, including finance, agriculture, foreign affairs

For more on **affordable access to asthma drugs** see <http://www.globaladf.org>

and trade, justice, education, urban design, and transport, have to be part of the whole-of-government response, along with civil society and the private sector. Core funding for programmes for NCDs has to come from the governments and be included in costed national health plans.⁶⁶

Prevention

The response to the crisis in NCD requires a strong focus on primary prevention, which is the only approach that will ensure future generations are not at risk of premature death from these diseases. Tobacco control and salt reduction are the top priorities. These population-wide approaches are highly feasible, cost effective, and will have an immediate and positive effect in the short term⁶⁷ and are cheap to implement—about US\$0·20 cents per person per year in China and India (table). Tobacco control is supported by the widely ratified FCTC; salt reduction can be largely achieved by reformulation of processed foods and salt substitution. The other population-wide interventions will have enormous health benefits; however, opposing vested interests will need to be overcome.⁶⁸

Treatment services

Implementation of the immediate priority treatment interventions needs a functioning health-care system and a stepwise approach.⁶⁹ Many health services are inadequate in terms of governance arrangements and health planning processes; health financing; health workers with appropriate skills; essential drugs and technologies; health-information systems; and health-services delivery models for long-term patient-centred care that is universally accessible. A key requirement is a comprehensive approach to health-systems strengthening to deliver services for all common diseases during the lifetime, with a patient-centred model of delivery.⁷⁰ A welcome shift is towards strengthened primary health care as part of a service hub that provides the support needed to deliver these critical prevention and treatment services for NCDs.⁷¹ For example, opportunistic screening of adults attending primary health-care facilities¹⁰ and the application of WHO's charts for assessment of cardiovascular risk,^{56,72} with advice for tobacco cessation, are realistic first steps in countries with functioning primary health-care systems.

Universal coverage through removal of financial and other barriers to access, particularly for people who are poor, is a priority but political commitment will be needed.⁷³ The financial protection strategies for efficient use of resources include cash transfers to reduce the costs of accessing services, reduction of user fees, extension of prepayment, and risk-pooling schemes that would benefit all health-care users.⁷⁴

International cooperation

Until now, NCDs have been neglected by development agencies, foundations, and global health agencies. An

effective response to NCDs requires government leadership and coordination of all relevant sectors and stakeholders, reinforced through international cooperation. International partners, including foundations, will play a special part in supporting further action on NCDs by funding and aligning these diseases with other priority development programmes such as the MDGs and climate change.

WHO is the lead international organisation for the prevention and treatment of NCD, but requires support from other organisations, including the World Bank, UN Development Programme, World Trade Organization, Food and Agriculture Organization, UN Children's Fund, UN Programme on HIV/AIDS, UN Population Fund, Organisation for Economic Co-operation and Development (OECD), and the World Customs Organization. Increased resources, particularly from extrabudgetary contributions by member states and donors, will be needed to support WHO's leadership. Cooperation between the international development agencies and donors may require the establishment of a multiagency task force reporting to the UN General Assembly.⁷⁵

For the private sector, the World Economic Forum presents an opportunity for cooperation and alignment of interests related to global public health goals. These goals will need to be monitored independently. The recently formed NCD Alliance, representing 880 member organisations in 170 countries, is a positive initiative for cooperation among international non-governmental organisations to achieve common goals for NCDs. Additionally, the major development non-governmental organisations should also become involved in tackling NCDs.

Monitoring, reporting, and accountability

A framework for national and global monitoring, reporting, and accountability is essential to ensure that the returns on investments in NCDs meet the expectations of all partners.⁷⁶ Accurate and complete registration of deaths by cause through national registration systems will be the most sustainable mechanism to monitor progress in prevention of NCDs. This goal is long term for many low-income and middle-income countries. Sample Registration System and the National Disease Surveillance Points system, as adopted by the Indian and Chinese governments, provide robust ways of monitoring causes of deaths in adults.^{77,78} Regular representative population surveys are effective ways to monitor trends in key risk factors and the uptake of priority interventions; an example is the WHO STEPS approach to surveillance of risk factors for NCDs.⁷⁹

Country-based institutional processes are needed for review of progress towards nationally and internationally agreed targets for NCDs as one component of a costed national health plan. We suggest, as have other groups

For more on NCD Alliance see
<http://www.ncdalliance.org>

for women's and children's health,⁸⁰ that independent national health commissions should take responsibility for reporting progress in NCDs, mobilising resources, developing policy, identifying best practices, building partnerships, identifying research priorities, and advocacy. Globally, national progress should be monitored by an independently funded expert group or a multiagency taskforce, such as the high-level taskforce for the global food security crisis.⁸¹ This taskforce would report regularly to the UN General Assembly through the Secretary General, World Health Assembly, and other key leadership forums such as the G8, G20, and G70 groups.

Conclusions

Many possible actions for the prevention and treatment of NCDs could be discussed in the lead-up to the UN HLM on NCDs in September, 2011. A clear and focused set of requests for consideration at the meeting will have the best chance of success.⁶⁶ The principles of simplicity and focus have informed this report, with the secure evidence base used to select the priority interventions for NCD, which will also have enormous ancillary benefits within the health sector and reduce comorbidities (panel 6). Prevention of NCDs is also inextricably linked with climate change and the need for low-carbon policies. Together these two agendas can achieve the synergies needed to overcome the barriers to change that result from vested interests and inertia.^{82,83} The potential dividend from a low-carbon economy highlights the direct link between the UN HLM and the UN Conference on Sustainable Development in 2012.

We recognise that many important issues are not explicitly addressed in our recommendations—eg, the early origins of many risk factors for NCDs before, during, and immediately after childbirth.⁴¹ This evidence places the prevention of NCDs as a development issue of great relevance to the agenda for women's and children's health. The immediate priority interventions—tobacco control, improved nutrition, and addressing cardiovascular risk factors—would all benefit maternal and infant health and have a positive effect on subsequent risks of NCDs. Indeed, all the proposals in this report will help to meet international obligations to respect, protect, and achieve the right to health.

Our top priority is tobacco control, and we propose a goal to achieve a world essentially free from tobacco by 2040—ie, a prevalence of less than 5%. We are confident that once large countries, such as China, begin to take tobacco control seriously, rapid progress will be achieved. Some countries will set an earlier date for achievement of this goal; the New Zealand Government has agreed to the goal of the country becoming a smoke-free nation by 2025.⁸⁴ The other top priority intervention is salt reduction with a goal of 5 g per person per year by 2025. The Pan American Health Organization has already established a goal of 5 g by 2020.

Panel 6: Examples of mutually reinforcing co-benefits of priority actions for non-communicable diseases

Health benefits

Reductions in:

- Blindness, amputations, and other complications of diabetes
- Dental caries
- Domestic violence
- Infectious diseases—eg, tuberculosis
- Injuries, including road traffic injuries, and falls
- Maternal and infant mortality and morbidity
- Renal diseases

Other benefits

Reductions in:

- Carbon footprint and greenhouse gases
- Environmental pollution
- Poverty

Improvements in:

- Built environments
- Economic growth and productivity
- Local food production
- Social interaction

Actions can be initiated and strengthened to address the other modifiable risk factors based on the strategies that have been endorsed by WHO member states. The success of these interventions depends on the ability of governments to resist pressure, in all forms, from powerful industries and their political supporters; hence the importance of a strong national and international civil society movement to press for change. The most challenging need relates to health-systems strengthening. We suggest that steps be taken, to develop primary health-care hubs at the lowest possible level of the health-care system with essential infrastructure and human resources.

The costs of the priority interventions for NCD are likely to be small—eg, the yearly cost to implement three priority interventions (tobacco control, salt reduction, and treatment of cardiovascular risk) in 23 high-burden countries was estimated in 2007 to be about \$6 billion, implying a new global commitment of about \$9 billion per year.¹¹ These estimates are now being updated by WHO for 42 high-burden low-income and middle-income countries. Implementation of priority interventions does not need a new global fund. The two most important actions—full implementation of tobacco control and salt reduction—are affordable in all countries. To implement the other priority interventions, countries will need to find new resources, which for many would be well within their existing and growing health-care budgets, especially if they use existing resources more efficiently and develop innovative funding mechanisms such as health promotion foundations funded by additional alcohol and tobacco taxes.

For more on the 2020 salt goal see http://new.paho.org/hq/index.php?option=com_content&task=view&id=2022&Itemid=1766

International partners and foundations have a special role in supporting intensified action on NCDs. They are expected to raise the priority of NCDs in their development agendas, which will lead to increased funding and innovative approaches to complement available national resources. Support for NCDs has to be aligned with other priority development programmes that are addressing important global initiatives such as the MDGs. A key challenge is to ensure that NCDs are central to the post-MDG development era.

An ideal outcome of the UN HLM will be a sustained commitment to a set of feasible actions and interventions for which specific and timed targets and indicators can be developed, and progress can be readily measured. The recommended commitments outlined in panel 5 are practical and can be achieved by all countries and international agencies. The UN HLM is a turning point in the way we approach global health issues, and it will place NCDs on the development agenda. The global community has to take this opportunity, and sustain the momentum to achieve the goal of avoiding premature NCD deaths and disability, thus improving global health in the years to come.

Contributors

RBe provided overall leadership and guidance on the development of the paper. RBe and RBo prepared the first and subsequent drafts with major inputs from GA, VB, SE, RG, GG, AH, JH, RH, PJ, PL, RM, MM, PP, and DS. All authors contributed to the successive drafts. Several authors contributed especially to specific sections: CA, NB, TC, RC, SC, AK, and JR contributed especially to the sections on treatment; SC and NS on alcohol; PA, PJ, JM, and JW on tobacco use; AH on environment; RM and DS on legal aspects; and HB and MR on health systems. MC and FS contributed especially to the table, RG to figure 1, and CV to panel 6.

Conflicts of interest

PA has received grants from Wellcome Trust Clinical PhD Fellowship. SE has received grants from the Wellcome Trust, and royalties from McGraw Hill for editing a book. RH is the editor of *The Lancet*. TG has received consultancy payments from Family Health International and Inter-American Development Bank; and payment for lectures, including lectures on speakers bureaus, from Network for Continuing Medical Education. BN has received consultancy payments from Bayer, payment for lectures including service on speakers bureaus from Allergan, and royalties for a book published by Karolinska University Press. BN's institute has received money for consultancy from Syngis, Servier, Bayer, Photothera, and Boehringer-Ingelheim. JT has received or has grants pending from Corporate Partners, Pfizer, Wiley, Sanofi-Aventis, Varian Medical Systems, Roche, Boehringer Ingelheim, Novartis, Slender, Merck, Eli Lilly, Heng Rui, and Irmet. The other authors declare that they have no conflicts of interest.

Acknowledgments

We thank the National Heart Forum for providing financial, technical, and administrative support for the production of this report. The authors alone are responsible for the views expressed in this report and they do not necessarily represent the decisions, policy, or views of WHO, the World Bank, the OECD, or those of the member countries of these organisations.

References

- WHO. Preventing chronic diseases: a vital investment. Geneva: World Health Organization, 2005.
- Fidler DP. After the revolution: global health politics in a time of economic crisis and threatening future trends. 2008. http://www.ghgj.org/Fidler_After%20the%20Revolution.pdf (accessed Feb 21, 2011).
- Engelau MM, El-Saharty S, Kudesai P, et al. Capitalizing on the demographic transition: Tackling noncommunicable disease in South Asia. http://siteresources.worldbank.org/SOUTHASIAEXT/Resources/223546-1296680097256/7707437-1296680114157/NCDs_South_Asia_February_2011.pdf (accessed Feb 21, 2011).
- UN. Prevention and control of non-communicable disease. New York: United Nations, 2010. http://www.who.int/mediacentre/news/notes/2010/noncommunicable_diseases_20100514/en/index.html (accessed Feb 21, 2011).
- Alleyne G, Stuckler D, Alwan A. The hope and the promise of the UN Resolution on non-communicable diseases. *Global Health* 2010; **6**: 15.
- Piot P, Ebrahim S. Prevention and control of chronic diseases. *BMJ* 2010; **341**: c4865.
- Hospedales CJ, Cummings SA, Gollop G, Greene E. Raising the priority of chronic non-communicable disease in the Caribbean. *Pan Am J Pub Health* (in press).
- Strong K, Mathers C, Leeder S, Beaglehole R. Preventing chronic diseases: how many lives can we save. *Lancet* 2005; **366**: 1578–82.
- Asaria P, Chisholm D, Mathers C, Ezzati M, Beaglehole R. Chronic disease prevention: health effects and financial costs of strategies to reduce salt intake and control tobacco use. *Lancet* 2007; **70**: 2044–53.
- Lim SS, Gaziano TA, Gakidou E, et al. Prevention of cardiovascular disease in high-risk individuals in low-income and middle-income countries: health effects and costs. *Lancet* 2007; **370**: 2054–62.
- Beaglehole R, Ebrahim S, Reddy S, et al. Prevention of chronic diseases: a call to action. *Lancet* 2007; **307**: 2152–57.
- Rehm J, Mathers C, Popova S, et al. Global burden of disease and injury and economic cost attributable to alcohol use and alcohol-use disorders. *Lancet* 2009; **373**: 2223–33.
- Anderson P, Chisholm D, Fuhr D. Effectiveness and cost-effectiveness of policies and programmes to reduce the harm caused by alcohol. *Lancet* 2009; **373**: 2234–46.
- Casswell S, Thamarangsi T. Reducing the harm from alcohol: call to action. *Lancet* 2009; **373**: 2247–57.
- Geneau R, Stuckler D, Stachenko S, et al. Raising the priority of preventing chronic diseases: a political process. *Lancet* 2010; **376**: 1689–98.
- Cecchini M, Sassi F, Lauer JA, et al. Tackling of unhealthy diets, physical inactivity, and obesity: health effects and cost-effectiveness. *Lancet* 2010; **376**: 1775–84.
- Alwan A, Maclean DR, Riley LM, et al. Monitoring and surveillance of chronic non-communicable diseases: progress and capacity in high-burden countries. *Lancet* 2010; **376**: 1861–68.
- Horton R. The neglected epidemic of chronic disease. *Lancet* 2005; **366**: 1514.
- Horton R. Chronic diseases: the case for urgent action. *Lancet* 2007; **370**: 1881–82.
- Beaglehole R, Horton R. Chronic diseases must match global evidence. *Lancet* 2010; **376**: 1619–21.
- Beaglehole R, Bonita R. Alcohol: a global priority. *Lancet* 2009; **373**: 2173–74.
- WHO. Action plan for the global strategy for the prevention and control of noncommunicable diseases. Geneva: World Health Organization, 2008.
- WHO. Mortality and burden of disease estimates for WHO Member States in 2004. Geneva: World Health Organization, 2009.
- Stuckler D. Population causes and consequences of leading chronic diseases: A comparative analysis of prevailing explanations. *Milbank Q* 2008; **86**: 273–326.
- WHO. Commission on the Social Determinants of health. Geneva: World Health Organization, 2008.
- Yusuf S, Hawken S, Ounpuu S, et al. Effects of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART Study): case control study. *Lancet* 2004; **364**: 937–52.
- Jha P, Peto R, Zatonski W, et al. Social inequalities in male mortality, and in male mortality from smoking: indirect estimation from national death rates in England and Wales, Poland, and North America. *Lancet* 2006; **368**: 367–70.
- Malone R. The tobacco Industry. In: Wiist W, ed. The bottom line or public health: tactics corporations use to influence health and health policy, and what we can do to counter them. New York: Oxford University Press, 2010.

- 29 Freeman B, Chapman S. British American tobacco on Facebook: undermining Article 13 of the global World Health Organization Framework Convention on Tobacco Control. *Tob Control* 2010; **19**: e1–9.
- 30 WHO. Risk factor estimates for 2004. www.who.int/healthinfo/global_burden_disease/risk_factors/en/index.html (accessed Feb 21, 2011).
- 31 Joffres M, Campbell NRC, Manns B, Tu K. Estimate of the benefits of a population-based reduction in dietary sodium additives on hypertension and its related health care costs in Canada. *Can J Cardiol* 2007; **23**: 437–43.
- 32 Casswell S, You RQ, Huckle T. Alcohol's harm to others: reduced wellbeing and health status for those with heavy drinkers in their lives. *Addiction* 2011; published online March 7. DOI:10.1111/j.1360-0443.2011.03361.x.
- 33 Leon DA, Saburova L, Tomkins S, et al. Hazardous alcohol drinking and premature mortality in Russia: a population based case-control study. *Lancet* 2007; **369**: 2001–09.
- 34 Rayner G, Hawkes C, Lang T, Bello W. Trade liberalization and the diet transition: A public health response. *Health Promot Int* 2006; **21**: 67–74.
- 35 Mahal A, Karan A, Engelau M. The economic implications of non communicable disease for India. Washington: World Bank, 2010.
- 36 WHO. Tobacco and poverty: a vicious cycle. Geneva: World Health Organization, 2004.
- 37 Stuckler D, Basu S, McKee M. Drivers of inequalities in Millennium Development Goal progress: A statistical analysis. *PLoS Med* 2010; **7**: e1000241.
- 38 World Economic Forum. Global risks 2011. <http://riskreport.weforum.org/> (accessed Feb 21, 2011).
- 39 Dooley KE, Chaison RE. Tuberculosis and diabetes mellitus: convergence of two epidemics. *Lancet Infect Dis* 2009; **9**: 737–46.
- 40 Jha P, Jacob B, Gajalakshmi V, Gupta PC et al. A nationally representative case-control study of smoking and death in India. *N Eng J Med* 2008; **358**: 1137–47.
- 41 Gluckman P, Hanson M. Mismatch. Why our world no longer fits our bodies. Oxford: Oxford University Press, 2006.
- 42 Gaziano TA, Galea G, Reddy KS. Scaling up interventions for chronic disease prevention. *Lancet* 2007; **370**: 1939–46.
- 43 Jamison DT, Breman JG, Measham AR, et al. Disease control priorities in developing countries, 2nd edn. Washington, Oxford: World Bank, Oxford University Press, 2006.
- 44 Jha P, Chaloupka FJ. Curbing the epidemic: governments and the economics of tobacco control. Washington: World Bank, 1999.
- 45 WHO. WHO Report on the global tobacco epidemic, 2009. The MPOWER package. Geneva: World Health Organization, 2009.
- 46 Lightwood JM, Glantz SA. Short-term economic and health benefits of smoking cessation: myocardial infarction and stroke. *Circulation* 1997; **96**: 1089–96.
- 47 Sims M, Maxwell R, Bauld L, Gilmore A. Short term impact of smoke-free legislation in England: retrospective analysis of hospital admissions for myocardial infarction. *Br Med J* 2010; **340**: c2161.
- 48 Verkaik-Kloosterman J, van 't Veer P, Ocké MC. Reduction of salt: will iodine intake remain adequate in The Netherlands? *Br J Nutr* 2010; **104**: 1712–18.
- 49 Group CSSSC. Salt substitution: a low-cost strategy for blood pressure control among rural Chinese. A randomized, controlled trial. *J Hypertens* 2007; **25**: 2011–18.
- 50 Cobiac LJ, Vos T, Veerman JL. Cost-effectiveness of interventions to reduce dietary salt intake. *Heart* 2010; **96**: 1920–25.
- 51 WHO. Prevention of cardiovascular disease: guidelines for assessment and management of cardiovascular risk. Geneva: World Health Organization, 2007.
- 52 Lock K, Pomerleau J, Causer L, Altmann DR, McKee M. The Global Burden of Disease due to low fruit and vegetable consumption: implications for the global strategy on diet. *Bull WHO* 2005; **83**: 100–08.
- 53 WHO. Global strategy on diet, physical activity and health. Geneva: World Health Organization, 2004. <http://www.who.int/dietphysicalactivity/publications/recsmarketing/en/index.html> (accessed Feb 21, 2011).
- 54 Chow CK, Lock K, Teo K, Subramanian SV, McKee M, Yusuf S. Environmental and societal influences acting on cardiovascular risk factors and disease at a population level: a review. *Int J Epidemiol* 2009; **38**: 1580–94.
- 55 Younger M, Morrow-Almeida H, Vindigni S, Dannenberg A. The built environment, climate change, and health: opportunities and co-benefits. *Am J Prev Med* 2008; **35**: 517–26.
- 56 WHO. Package of essential noncommunicable (PEN) disease interventions for primary health care in low-resource settings. Geneva: World Health Organization, 2010.
- 57 Gaziano TA, Young CR, Fitzmaurice G, Atwood S, Gaziano JM. Laboratory-based versus non-laboratory-based method for assessment of cardiovascular disease risk: the NHANES I Follow-up Study cohort. *Lancet* 2008; **371**: 923–31.
- 58 Gill GV, Yudkin JS, Keen H, Beran D. The insulin dilemma in resource-limited countries. A way forward? *Diabetologia* 2011; **54**: 19–24.
- 59 UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). *Lancet* 1998; **352**: 837–53.
- 60 Farmer P, Frenk J, Knaul FM et al. Expansion of cancer care and control in countries of low and middle income: a call to action. *Lancet* 2010; **376**: 1186–93.
- 61 Outtersson K, Kesselheim A. Market-based licensing for HPV vaccines in developing countries. *Health Aff* 2008; **27**: 130–39.
- 62 Callaway M, Foley KM, De Lima L, et al. Funding for palliative care programs in developing countries. *J Pain Symptom Manage* 2007; **33**: 509–13.
- 63 Daar AS, Singer PA, Persad DL, et al. Grand challenges in chronic non-communicable diseases. *Nature* 2007; **450**: 494–96.
- 64 Institute of Medicine. Promoting cardiovascular health in the developing world: a critical challenge to achieve global health. Washington DC: Institute of Medicine, 2010.
- 65 Shiffman J, Smith S. Generation of political priority for global health initiatives: a framework and case study of maternal mortality. *Lancet* 2007; **370**: 1370–79.
- 66 Sridhar D, Morrison JS, Piot P. Getting the politics right for the September 11 UN High-Level Meeting on Noncommunicable Diseases. Washington DC: Centre for Strategic and International Studies, 2011.
- 67 Capewell S, O'Flaherty M. Rapid mortality falls after risk factor changes in populations. *Lancet* 2011; published online March 16. DOI:10.1016/S0140-6736(10)62302-1.
- 68 Knai C, Gilmore A, Lock K, McKee M. Public health research funding: independence is important. *Lancet* 2010; **376**: 75–77.
- 69 Epping-Jordan JE, Galea G, Tukuitoronga C, Beaglehole R. Preventing chronic diseases: taking stepwise action. *Lancet* 2005; **366**: 1667–71.
- 70 Balabanova D, McKee M, Mills A, Walt G, Haines A. What can global health institutions do to help strengthen health systems in low income countries? *Health Res Policy Syst* 2010; **8**: 22.
- 71 Beaglehole R, Epping-Jordan J, Patel V, et al. Improving the prevention and management of chronic disease on low-and middle income countries: a priority for primary health care. *Lancet* 2008; **372**: 940–49.
- 72 Lindholm L, Mendis S. Prevention of cardiovascular disease in developing countries. *Lancet* 2007; **370**: 720–22.
- 73 Stuckler D, Feigl AB, Basu S, McKee M. The political economy of universal health coverage. Background paper for the global symposium on health systems research. Geneva: World Health Organization, 2010.
- 74 WHO. World Health Report—health systems financing: the path to universal coverage. Geneva: World Health Organization, 2010.
- 75 Magnusson R. Rethinking global health challenges: towards a 'Global Compact' for reducing the burden of chronic disease. *Public Health* 2009; **123**: 265–74.
- 76 GHME Conference Organising Committee. Shared innovations in measurement and evaluation. *Lancet* 2011; published online March 14. DOI:10.1016/S0140-6736(11)60169-4.
- 77 RGI/CGHR. Causes of death in India in 2001–003. New Delhi: Registrar General, Government of India, 2009.

- 78 Yang G, Hu J, Rao KQ, Ma J, Rao C, Lopex AD. Mortality registration and surveillance in China: history, current situation and challenges. *Popul Health Metr* 2005; 3: 3.
- 79 WHO. STEPwise approach to surveillance (STEPS). <http://www.who.int/chp/steps/en> (accessed Feb 21, 2011).
- 80 The Lancet. The benefits of recession. *Lancet* 2011; 377: 783.
- 81 UN. Comprehensive Framework for Action. High-level taskforce on the global food security crisis. 2008. <http://www.un.org/issues/food/taskforce/Documentation/CFA%20Web.pdf> (accessed Feb 28, 2011).
- 82 Haines A, McMichael AJ, Smith KR, et al. Public health benefits of strategies to reduce greenhouse-gas emissions: overview and implications for policy makers. *Lancet* 2009; 374: 2104–14.
- 83 UN Framework Convention on Climate Change. Conference of the Parties, 15th session, Copenhagen Accord: Copenhagen, Dec 18, 2009. <http://unfccc.int/resource/docs/2009/cop15/eng/107.pdf> (accessed March 26, 2011).
- 84 New Zealand Government. Government response to the report of the Māori Affairs Committee on its inquiry into the tobacco industry in Aotearoa and the consequences of tobacco use for Māori (final response). http://www.parliament.nz/NR/rdonlyres/3AAA09C2-AD68-4253-85AE-BCE90128C1A0/187795/DBHOH_PAP_21175_GovernmentFinalResponsetoReportoft.pdf (accessed on March 21, 2011).